C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
C4 Therapeutics has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
C4 Therapeutics's investors include RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Roche, Novartis.
C4 Therapeutics is headquartered in Cambridge, United States.
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
C4 Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"C4 Therapeutics — Funding & Investors." VCBacked, October 16, 2025, https://www.vcbacked.co/company/c4-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). C4 Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/c4-therapeutics
{{cite web |title=C4 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/c4-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated